The current financial score of Silo Pharma Inc is 6.23. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 30.84%.
The current valuation score of Silo Pharma Inc is 8.72. Its current P/E ratio is -3.68, which is -91.60% below the recent high of -0.31 and -433.11% above the recent low of -19.59.
No earnings forecast score is currently available for Silo Pharma Inc. The Pharmaceuticals industry's average is 7.83.
The current price momentum score of Silo Pharma Inc is 7.18. Currently, the stock price is trading between the resistance level at 2.00 and the support level at 1.10, making it suitable for range-bound swing trading.
The current institutional shareholding score of Silo Pharma Inc is 3.00. The latest institutional shareholding proportion is 8.05%, representing a quarter-over-quarter decrease of 31.14%.
The current risk assessment score of Silo Pharma Inc is 1.99. The company's beta value is 0.75. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.